The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats

Biomaterials

Volumn 32, Issue 31, 2011, Pages 7988-7998

  Wang, Yong Tang ^a   Lu, Xiu Min ^b   Zhu, Feng ^b   Huang, Peng ^b   Yu, Ying ^b   Zeng, Lin ^a   Long, Zai Yun ^a   Wu, Ya Min ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHONGQING UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Functional recovery; GNPs; HNgR Fc; Protein vaccine; Spinal cord injury

Indexed keywords

AXON REGENERATION; AXONAL REGENERATION; CENTRAL NERVOUS SYSTEMS; CLINICAL APPLICATION; FUNCTIONAL RECOVERY; FUSION PROTEINS; GNPS; GOLD NANOPARTICLES; HNGR-FC; IMMUNE RESPONSE; IMMUNOGENICITY; IN-VITRO; INHIBITORY ACTIVITY; NEURITE OUTGROWTH; NEURONAL LOSS; NEUROPROTECTION; NOGO-66 RECEPTORS; PHYSIOLOGICAL DAMAGES; PROTEIN IMMUNIZATION; RECOMBINANT PROTEIN; SIDE EFFECT; SPINAL CORD INJURY; SPINAL CORDS; THERAPEUTIC EFFICACY; VACCINATION STRATEGY;

DOSIMETRY; EMULSIFICATION; IMMUNIZATION; NANOPARTICLES; PATIENT REHABILITATION; PHYSIOLOGICAL MODELS; RATS; RECOVERY; VACCINES;

PROTEINS;

ANTIBODY; FC RECEPTOR; FREUND ADJUVANT; GOLD NANOPARTICLE; HYBRID PROTEIN; NOGO 66 RECEPTOR; NOGO 66 RECEPTOR ANTIBODY; RECOMBINANT HUMAN NOGO 66 RECEPTOR FC RECEPTOR FUSION PROTEIN VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL ASSESSMENT; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOTOR PERFORMANCE; NERVE FIBER GROWTH; NERVE FIBER REGENERATION; NEUROPROTECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYRAMIDAL TRACT; RAT; SPINAL CORD INJURY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; AXONS; GAP-43 PROTEIN; GOLD; GPI-LINKED PROTEINS; HUMANS; IMMUNE SERA; IMMUNIZATION; METAL NANOPARTICLES; MYELIN PROTEINS; NERVE REGENERATION; NEURITES; NEUROPROTECTIVE AGENTS; RATS; RECEPTORS, CELL SURFACE; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; RECOVERY OF FUNCTION; SPINAL CORD; SPINAL CORD INJURIES; TREATMENT OUTCOME; VACCINES; WOUND HEALING;

MAMMALIA; RATTUS;

EID: 80051819208     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.07.009     Document Type: Article

References (50)

1. Chen M.S., Huber A.B., van der Haar M.E., Frank M., Schnell L., Spillmann A.A., et al. Nogo-A is a myelin-associated neurite outgrowth inhibitor and an antigen for monoclonal antibody IN-1. Nature 2000, 403:434-439.
2. GrandPre T., Nakamura F., Vartanian T., Strittmatter S.M. Identification of the Nogo inhibitor of axon regeneration as a Reticulon protein. Nature 2000, 403:439-444.
3. Prinjha R., Moore S.E., Vinson M., Blake S., Morrow R., Christie G., et al. Inhibitor of neurite outgrowth in humans. Nature 2000, 403:383-384.
4. McKerracher L., David S., Jackson D.L., Kottis V., Dunn R.J., Braun P.E. Identification of myelin-associated glycoprotein as a major myelin-derived inhibitor of neurite growth. Neuron 1994, 13:805-811.
5. Mukhopadhyay G., Doherty P., Walsh F.S., Crocker P.R., Filbin M.T. A novel role for myelin-associated glycoprotein as an inhibitor of axonal regeneration. Neuron 1994, 13:757-767.
6. Kottis V., Thibault P., Mikol D., Xiao Z.C., Zhang R., Dergham P., et al. Oligodendrocyte-myelin glycoprotein (OMgp) is an inhibitor of neurite outgrowth. Journal of Neurochemistry 2002, 82:1566-1569.
7. Fournier A.E., GrandPre T., Strittmatter S.M. Identification of a receptor mediating Nogo-66 inhibition of axonal regeneration. Nature 2001, 409:341-346.
8. Liu B.P., Fournier A., GrandPre T., Strittmatter S.M. Myelin-associated glycoprotein as a functional ligand for the Nogo-66 receptor. Science 2002, 297:1190-1193.
9. Wang K.C., Koprivica V., Kim J.A., Sivasankaran R., Guo Y., Neve R.L., et al. Oligodendrocyte-myelin glycoprotein is a Nogo receptor ligand that inhibits neurite outgrowth. Nature 2002, 417:941-944.
10. McGee A.W., Strittmatter S.M. The Nogo-66 receptor: focusingmyelin inhibition of axon regeneration. Trends in Neurosciences 2003, 26:193-198.
11. Mi S., Lee X., Shao Z., Thill G., Ji B., Relton J., et al. LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex. Nature Neuroscience 2004, 7:221-228.
12. Wang K.C., Kim J.A., Sivasankaran R., Segal R., He Z. P75 interacts with the Nogo receptor as a co-receptor for Nogo, MAG and OMgp. Nature 2002, 420:74-78.
13. Yamashita T., Higuchi H., Tohyama M. The p75 receptor transduces the signal from myelin-associated glycoprotein to Rho. Journal of Cell Biology 2002, 157:565-570.
14. Park J.B., Yiu G., Kaneko S., Wang J., Chang J., He Z. A TNF receptor family member, TROY, is a coreceptor with Nogo receptor in mediating the inhibitory activity of myelin inhibitors. Neuron 2005, 45:345-351.
15. Shao Z., Browning J.L., Lee X., Scott M.L., Shulga-Morskaya S., Allaire N., et al. TAJ/TROY, an prphan TNF receptor family member, binds Nogo-66 receptor 1 and regulates axonal regeneration. Neuron 2005, 45:353-359.
16. Schwartz M., Moalem G., Leibowitz-Amit R., Cohen I.R. Innate and adaptive immune responses can be beneficial for CNS repair. Trends in Neurosciences 1999, 22:295-299.
17. Hauben E., Butovsky O., Nevo U., Yoles E., Moalem G., Agranov E., et al. Passive or active immunization with myelin basic protein promotes recovery from spinal cord contusion. The Journal of Neuroscience 2000, 20:6421-6430.
18. Kipnis J., Yoles E., Schori H., Hauben E., Shaked I., Schwartz M. Neuronal survival after CNS insult is determined by a generically encoded autoimmune response. The Journal of Neuroscience 2001, 21:4564-4571.
19. Yoles E., Hauben E., Dalgi O., Agranov E., Gothilf A., Cohen A., et al. Protective autoimmunity is a physiological response to CNS trauma. The Journal of Neuroscience 2001, 21:3740-3748.
20. Cohen I.R., Schwartz M. Autoimmune maintenance and neuroprotection of the central nervous system. Journal of Neuroimmunology 1999, 100:111-114.
21. Yu P., Huang L., Zou J., Zhu H., Wang X., Yu Z., et al. DNA vaccine against NgR promotes functional recovery after spinal cord injury in adult rats. Brain Research 2007, 1147:66-76.
22. Yu P., Huang L., Zou J., Yu Z., Wang Y., Wang X., et al. Immunization with recombinant Nogo-66 receptor (NgR) promotes axonal regeneration and recovery of function after spinal cord injury in rats. Neurobiology of Disease 2008, 32:535-542.
23. Wilson-Welder J.H., Torres M.P., Kipper M.J., Mallapragada S.K., Wannemuehler M.J., Narasimhan B. Vaccine adjuvants: current challenges and future approaches. Journal of Pharmaceutical Sciences 2009, 98:1278-1316.
24. Caruthers S.D., Wickline S.A., Lanza G.M. Nanotechnological applications in medicine. Current Opinion in Biotechnology 2007, 18:26-30.
25. Huang Y., Yu F., Park Y.S., Wang J., Shin M.C., Chung H.S., et al. Co-administration of protein drugs with gold nanoparticles to enable percutaneous delivery. Biomaterials 2010, 31:9086-9091.
26. Kogan M.J., Olmedo I., Hosta L., Guerrero A.R., Cruz L.J., Albericio F. Peptides and metallic nanoparticles for biomedical applications. Nanomedicine 2007, 2:287-306.
27. Lasagna-Reeves C., Gonzalez-Romero D., Barria M.A., Olmedo I., Clos A., Sadagopa Ramanujm V.M., et al. Bioaccumulation and toxicity of gold nanoparticles after repeated administration in mice. Biochemical and Biophysical Research Communications 2010, 393:649-655.
28. Pan Y., Neuss S., Leifert A., Fischler M., Wen F., Simon U., et al. Size-dependent cytotoxicity of gold nanoparticles. Small 2007, 3:1941-1949.
29. Sonavane G., Tomoda K., Makino K. Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. Colloids and Surfaces B 2008, 66:274-280.
30. Sharma H.S., Muresanu D.F., Sharma A., Patnaik R., Lafuente J.V. Nanoparticles influence pathophysiology of spinal cord injury and repair. Progress in Brain Research 2009, 180:154-180.
31. Dykman L.A., Sumaroka M.V., Staroverov S.A., Zaitseva I.S., Bogatyrev V.A. Immunogenic properties of colloidal gold. The Biological Bulletin 2004, 31:75-79.
32. Dykman L.A., Staroverov S.A., Bogatyrev V.A., Shchyogolev S.Y. Adjuvant properties of gold nanoparticles. Nanotechnologies in Russia 2010, 5:748-761.
33. Bastús N.G., Sánchez-Tilló E., Pujals S., Farrera C., Kogan M.J., Giralt E., et al. Peptides conjugated to gold nanoparticles induce macrophage activation. Molecular Immunology 2009, 46:743-748.
34. Lee K., Lee H., Bae K.H., Park T.G. Heparin immobilized gold nanoparticles for targeted detection and apoptotic death of metastatic cancer cells. Biomaterials 2010, 31:6530-6536.
35. Zhu F., Wang Y.T., Lu X.M., Zeng L., Wu Y.M. Prokaryotic expression of recombinant human p75NTR-Fc fusion protein and its effect on the neurite outgrowth of dorsal root ganglia neuron. Journal of Medical Colleges of PLA 2009, 24:1-9.
36. Ji B., Case L.C., Liu K., Shao Z., Lee X., Yang Z., et al. Assessment of functional recovery and axonal sprouting in oligodendrocyte-myelin glycoprotein (OMgp) null mice after spinal cord injury. Molecular and Cellular Neuroscience 2008, 39:258-267.
37. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomoter ranting scale for open field testing in rats. Journal of Neurotrauma 1995, 12:1-21.
38. Merkler D., Metz G.A., Raineteau O., Dietz V., Schwab M.E., Fouad K. Locomotor recomotor recovery in spinal cord-injured rats treated with an antibody neutralizing the myelin-associated neurite growth inhibitor Nogo-A. The Journal of Neuroscience 2001, 21:3665-3673.
39. Stirling D.P., Khodarahmi K., Liu J., McPhail L.T., McBride C.B., StReeves J.D., et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. The Journal of Neuroscience 2004, 24:2182-2190.
40. Gage F.H. Mammalian neural stem cells. Science 2000, 287:1433-1438.
41. Decherchi P., Gauthier P. Regrowth of acute and chronic injured spinal pathways within supra-lesional post-traumatic nerve grafts. Neuroscience 2000, 101:197-210.
42. Teng Y.D., Mocchetti I., Wrathall J.R. Basic and acidic fibroblast growth factors protect spinal motor neurons in vivo after experimental spinal cord injury. European Journal of Neuroscience 1998, 10:798-802.
43. GrandPre T., Li S., Strittmatter S.M. Nogo-66 receptor antagonist peptide promotes axonal regeneration. Nature 2002, 417:547-551.
44. Li S., Strittmatter S.M. Delayed systemic Nogo-66 receptor antagonist promotes recovery from spinal cord injury. The Journal of Neuroscience 2003, 23:4219-4227.
45. Li S., Liu B.P., Budel S., Li M., Ji B., Walus L., et al. Blockade of Nogo-66, myelin-associated glycoprotein, and oligodendrocytemyelin glycoprotein by soluble Nogo-66 receptor promotes axonal sprouting and recovery after spinal injury. The Journal of Neuroscience 2004, 24:10511-10520.
46. Li W., Walus L., Rabacchi S.A., Jirik A., Chang E., Schauer J., et al. A neutralizing anti-Nogo66 receptor monoclonal antibody reverses inhibition of neurite outgrowth by central nervous system myelin. The Journal of Biological Chemistry 2004, 279:43780-43788.
47. Li S., Kim J.E., Budel S., Hampton T.G., Strittmatter S.M. Transgenic inhibition of Nogo-66 receptor function allows axonal sprouting and improved locomotion after spinal injury. Molecular and Cellular Neuroscience 2005, 29:26-39.
48. Huang D.W., McKerracher L., Braun P.E., David S. A therapeutic vaccine approach to stimulate axon regeneration in the adult mammalian spinal cord. Neuron 1999, 24:639-647.
49. Jiao X.D., Cheng S., Hu Y.H., Sun L. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen. Vaccine 2010, 28:1832-1837.
50. David S., Fry E.J., Lopez-Vales R. Novel roles for Nogo receptor in inflammation and disease. Trends in Neurosciences 2008, 31:221-226.